MX vs REKR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Magnachip (MX) exhibits severe fundamental distress, highlighted by a critical Piotroski F-Score of 0/9, indicating a total lack of improvement in financial health across all measured dimensions. While the company maintains a strong liquidity position with a Current Ratio of 4.07 and low debt (D/E 0.19), these are offset by a collapsing top line, with YoY revenue growth at -20.70% and Q/Q growth at -35.64%. The company is consistently unprofitable with negative operating margins of -30.68%, and the stock is trading at a significant discount to book value (P/B 0.48), suggesting the market is pricing in continued asset impairment or business model failure.
REKR exhibits severe financial distress, anchored by a critical Piotroski F-Score of 1/9 and a complete absence of positive earnings. The company is suffering from negative revenue growth (-4.40% YoY) and deep negative profit margins (-64.93%), indicating an inability to scale its software infrastructure business profitably. With a 5-year price collapse of 95.5% and a consistent track record of missing earnings estimates, the stock is currently a speculative vehicle rather than a fundamental investment. The lack of a Graham Number or Intrinsic Value further confirms the absence of a fundamental valuation floor.
Compare Another Pair
Related Comparisons
MX vs REKR: Head-to-Head Comparison
This page compares Magnachip Semiconductor Corporation (MX) and Rekor Systems, Inc. (REKR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.